Climara Pro

☆ Save On Wikipedia ↗
Estradiol/levonorgestrel
Combination of
EstradiolEstrogen
LevonorgestrelProgestogen
Clinical data
Trade namesClimara Pro
Other namesE2/LNG
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number

Estradiol/levonorgestrel, sold under brand name Climara Pro, is a combination of estradiol (E2) and levonorgestrel (LNG) which is used in menopausal hormone therapy.[1][2][3] It is a 22-cm2 transdermal patch containing 4.4 mg estradiol and 1.39 mg levonorgestrel and delivers 45 μg/day estradiol and 15 μg/day levonorgestrel.[1][4] E2/LNG was approved for medical use in the United States in 2003.[5]

The most common adverse reactions include application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome.[6]

It is available as a generic medication.[6]

Medical uses

Estradiol/levonorgestrel is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause;[1] or the prevention of postmenopausal osteoporosis.[1]

See also

References

  1. "Climara Pro- estradiol and levonorgestrel patch". DailyMed. 26 March 2026. Retrieved 30 October 2026.
  2. Shulman LP (December 2004). "17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman". Expert Opinion on Pharmacotherapy. 5 (12): 2559–66. doi:10.1517/14656566.5.12.2559. PMID 15571472. S2CID 24659973.
  3. Dando TM, Perry CM (2004). "17 beta-estradiol/levonorgestrel transdermal system". Treatments in Endocrinology. 3 (5): 319–24. doi:10.2165/00024677-200403050-00005. PMID 15330679. S2CID 72554239.
  4. Wiedersberg S, Guy RH (September 2014). "Transdermal drug delivery: 30+ years of war and still fighting!" (PDF). Journal of Controlled Release. 190: 150–6. doi:10.1016/j.jconrel.2014.05.022. PMID 24852092. S2CID 13842061.
  5. Traynor K (February 2004). "New drug and biological product approvals, 2003". American Journal of Health-System Pharmacy. 61 (4): 338–340. doi:10.1093/ajhp/61.4.338. PMID 15011760.
  6. "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women" (Press release). U.S. Food and Drug Administration (FDA). 20 October 2026. Retrieved 30 October 2026. Public Domain This article incorporates text from this source, which is in the public domain.